Abstract
Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The currently used combination drug regimens produce cure rates that exceed 95%, given good patient adherence during the multiple months treatment period. However the recent surge in HIV infections and the synergy between HIV and TB as well as the emergence of resistance resulted in an unforeseen increase in the number of TB cases, including multi-drug resistant (MDR) and extensively-drug resistant (XDR) forms of TB. Consequently, there is an urgent need to develop novel, fast acting antituberculosis drugs with high potency that can provide treatment options for all forms of TB. It is well known that the current TB drugs exhibit differences in their in vivo activity profile and these differences are largely determined by their pharmacodynamics (PD), i.e. intrinsic antibacterial activity, biopharmaceutical properties such as solubility and permeability, and pharmacokinetic (PK) properties such as drug exposure, tissue distribution, and protein binding. An understanding of the relationships among these properties is considered key for a rational use of antituberculosis therapeutics. The current review provides a comprehensive summary of physicochemical/biopharmaceutical, PK, and PD properties of currently used antituberculosis drugs and novel agents under development. Also, a brief review of PK/PD parameters of current TB drugs is given and properties of a desirable TB drug target and drug molecule are outlined. The information provided herewith may be useful in the optimization of biopharmaceutical and PK/PD characteristics in the development of novel TB therapeutics and in the design of optimal treatment regimens.
Keywords: Tuberculosis, antituberculosis drug, pharmacokinetics, pharmacodynamics, biopharmaceutics, drugs development
Current Medicinal Chemistry
Title: Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs
Volume: 15 Issue: 8
Author(s): Nageshwar R. Budha, Richard E. Lee and Bernd Meibohm
Affiliation:
Keywords: Tuberculosis, antituberculosis drug, pharmacokinetics, pharmacodynamics, biopharmaceutics, drugs development
Abstract: Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The currently used combination drug regimens produce cure rates that exceed 95%, given good patient adherence during the multiple months treatment period. However the recent surge in HIV infections and the synergy between HIV and TB as well as the emergence of resistance resulted in an unforeseen increase in the number of TB cases, including multi-drug resistant (MDR) and extensively-drug resistant (XDR) forms of TB. Consequently, there is an urgent need to develop novel, fast acting antituberculosis drugs with high potency that can provide treatment options for all forms of TB. It is well known that the current TB drugs exhibit differences in their in vivo activity profile and these differences are largely determined by their pharmacodynamics (PD), i.e. intrinsic antibacterial activity, biopharmaceutical properties such as solubility and permeability, and pharmacokinetic (PK) properties such as drug exposure, tissue distribution, and protein binding. An understanding of the relationships among these properties is considered key for a rational use of antituberculosis therapeutics. The current review provides a comprehensive summary of physicochemical/biopharmaceutical, PK, and PD properties of currently used antituberculosis drugs and novel agents under development. Also, a brief review of PK/PD parameters of current TB drugs is given and properties of a desirable TB drug target and drug molecule are outlined. The information provided herewith may be useful in the optimization of biopharmaceutical and PK/PD characteristics in the development of novel TB therapeutics and in the design of optimal treatment regimens.
Export Options
About this article
Cite this article as:
Budha R. Nageshwar, Lee E. Richard and Meibohm Bernd, Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs, Current Medicinal Chemistry 2008; 15 (8) . https://dx.doi.org/10.2174/092986708783955509
DOI https://dx.doi.org/10.2174/092986708783955509 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Function Prediction of Hypothetical Proteins Without Sequence Similarity to Proteins of Known Function (SUPPLEMENTARY MATERIALS)
Protein & Peptide Letters Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety Fluoroquinolones: An Important Class of Antibiotics Against Tuberculosis
Current Medicinal Chemistry Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Management of Certain Respiratory Disorders through Ayurveda: A Systematic Review of Clinical Studies Published in Ayurveda Journal
Current Traditional Medicine Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Inhaled Dry Powder Formulations for Treating Tuberculosis
Current Drug Delivery From Conventional Reaction Conditions to Microwave-Assisted Catalytic Transformations of Various Substrates. State of the Art in 2012 (Part A: General)
Current Organic Chemistry IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Transcriptional Regulation of Antimicrobial Host Defense Peptides
Current Protein & Peptide Science Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Tuberculosis - Present Medication and Therapeutic Prospects
Current Medicinal Chemistry Antigen Discovery for Serological Diagnosis of Visceral Leishmaniasis
Current Chemical Biology Targeting HIV: Past, Present and Future
Infectious Disorders - Drug Targets Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Polyphosphate Synthesis as a Target for Novel Antibiotics
Current Enzyme Inhibition